This study is looking at a new treatment for moderate to severely active Crohn’s Disease (CD) which is an inflammatory bowel disease (IBD). CD causes gastrointestinal signs and symptoms such as diarrhoea, abdominal pain, weight loss and passing blood or mucous. Current treatments for this highly complex disease have unacceptable side effects or cannot be used long term as they suppress the immune system and may increase the risk of serious infection or cancer.
This new treatment is believed to reduce the swelling that contributes to CD by blocking a specific part of your immune response pathway. There are a number of new treatments for CD which have been approved for use in other countries. This one is thought to be a better treatment for CD compared to these other medications as it is restricted to the gut and very unlikely to spread to other parts of the body, meaning it would have fewer side effects and remain in the gut. It will be administered as a capsule and hoped that it will be a better treatment for people with CD.
If you would like to find out more about the Crohn’s Study then please register below, call us on 1800 243 733 or email us at email@example.com